Back to the future—breast cancer reprises pathways found in fetal cells

August 7, 2018, Salk Institute
Pictured is mammary tissue of a developing mouse embryo at day 18, with cells that express both luminal protein (red) and basal protein (green). Cells in breast cancer often show this embryonic characteristic of expressing both proteins. Credit: Salk Institute

Using just a microscope, Italian surgeon Francesco Durante was struck by the similarities between cells in the most malignant cancers and the embryonic cells of the organ in which the cancer originated.

More than a century later, scientists at the Salk Institute have uncovered a reason for the uncanny likeness: cells in human basal-like breast cancers share features with the embryonic mammary (breast) stem cells that are the progenitors of all cell types in the mammary gland (of a mouse). The insights leading to this conclusion are published in the journal Cell Reports on August 7, 2018.

"Durante was prescient," says Professor Geoffrey Wahl, holder of the Daniel and Martina Lewis Chair and senior author of the work. "He anticipated the relatedness of cells in the embryo to those in malignant cancers—and that dormant cancer cells could be 'reawakened' by exposure to 'persistent irritations' that we now recognize as inflammation. We can use the insights gained from our work to develop better diagnostic and treatment strategies."

For example, human breast cancers share some peculiar metabolic features with early embryonic mammary stem cells, which may be possible to target therapeutically. Additionally, proteins specifically expressed in the embryonic cells that are also expressed in the cancers may be used to develop new diagnostic agents or tools for immune therapies.

Cancer has been called a "caricature of development," reprising features of the embryonic stem cell state for their own perverse purposes. So Wahl and his research group at Salk, along with investigator Benjamin Spike of the Huntsman Cancer Institute at the University of Utah, used cutting-edge techniques to generate an atlas of the genes expressed in each breast cell from very early in development until adulthood, a process that required an analysis of many thousands of cells. They used this "single-cell-transcriptome atlas" to compare genes expressed in human breast cancers. This led to an understanding of how the stem cells of the breast arise in early development and how they turn into the two different types of cells that comprise the mature gland.

A quote from Italian surgeon Francesco Durante, who in 1874 was struck by the similarities between cells in the most malignant cancers and the embryonic cells of the organ in which the cancer originated. Credit: Salk Institute
"There has been intense interest in determining how rare cells in tumors can fuel tumor growth and resistance to therapies," says Spike, who is an assistant professor of oncological sciences at the University of Utah and the paper's co-corresponding author. "Much of the molecular machinery they use to do this appears to be co-opted and corrupted from stem cells and progenitors that used this machinery to build the normal tissue during development. Our study provides an atlas of the responsible genes that can be tested for their potential as therapeutic targets."

"This work shows the diversity of ways that cells can enter the stem state, which is characterized by their plasticity, or developmental flexibility," adds first author Rajshekhar Giraddi, a Salk research associate in Wahl's lab. "This suggests that cancer cells may gain their plasticity by many strategies, similar to those we are discovering in normal development."

This developmental plasticity likely explains how the cells within a single tumor can appear so different from one another and likely underlies the uncanny ability of malignant cancer cells to become resistant to most therapies.

Now, armed with this knowledge of the genetic signatures of different cell states, the lab is developing new ways of looking at the reprogramming of adult cells into states associated with cancer.

"What would be great is if we can figure out how to prevent the reprogramming of cancer cells to become so developmentally plastic." says Wahl. "This plasticity will likely preclude development of a single 'magic bullet' to treat cancer. Rather, cancers are very adaptive diseases, requiring attacking them from multiple directions."

Explore further: Kidney cancers caught stealing genes from other cell types in order to spread

More information: Rajshekhar R. Giraddi et al, Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland Development, Cell Reports (2018). DOI: 10.1016/j.celrep.2018.07.025

Related Stories

Kidney cancers caught stealing genes from other cell types in order to spread

June 7, 2018
A study has identified how kidney cancers may develop the ability to spread around the body by hijacking genes from other cell types and 'stealing' their functions.

New breast cancer targets

May 4, 2018
Genome-wide association studies (GWAS) have identified more than 150 genetic variations associated with increased risk for breast cancer. Most of these variants are not located in protein-coding gene regions but are assumed ...

New genes associated with breast cancer risk

June 26, 2018
Only a small percentage of breast cancer cases can be linked to heredity, and many of the genes with ties to the disease are unknown.

Study reveals startlingly different tissue sensitivities to cancer-driving genes

March 22, 2018
New research led by Harvard Medical School and Brigham and Women's Hospital has unmasked hundreds of cancer-driving genes and revealed that different tissue types have shockingly variable sensitivities to those genes.

Genetic targets to chemo-resistant breast cancer identified

October 3, 2017
Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cancer.

Can mice really mirror humans when it comes to cancer?

January 18, 2018
A new Michigan State University study is helping to answer a pressing question among scientists of just how close mice are to people when it comes to researching cancer.

Recommended for you

Some brain tumors may respond to immunotherapy, new study suggests

December 10, 2018
Immunotherapy has proved effective in treating a number of cancers, but brain tumors have remained stubbornly resistant. Now, a new study suggests that a slow-growing brain tumor arising in patients affected by neurofibromatosis ...

Study finds higher risk of breast cancer for women after giving birth

December 10, 2018
Younger women who have recently had a child may have a higher risk of breast cancer than their peers of the same age who do not have children, according to a large-scale analysis co-led by a University of North Carolina Lineberger ...

A code for reprogramming immune sentinels

December 10, 2018
For the first time, a research team at Lund University in Sweden has successfully reprogrammed mouse and human skin cells into immune cells called dendritic cells. The process is quick and effective, representing a pioneering ...

Researchers develop personalized medicine tool for inherited colorectal cancer syndrome

December 10, 2018
An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes ...

Study shows key enzyme linked to therapy resistance in deadly lung cancer

December 10, 2018
Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth factor receptor (EGFR)-mutant non-small ...

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.